Danaher (DHR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Danaher's revenue growth inflected from -0.9% in 2025Q1 to 8.3% in 2026Q3 as bioprocessing destocking eased, with operating margin recovering to 19.0% from 16.5% in 2024Q3, suggesting the Life Sciences portfolio is normalizing though durability of end-demand w...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 8.3% in 2026Q3 with gross margin at 58.5% and operating margin at 19.0%, indicating incomplete but genuine operating leverage as SG&A discipline offsets a rising $433M R&D line.
Danaher is a leading global innovator in life sciences and diagnostics, committed to improving human health through science and technology.
The company has shown strong bioprocessing recovery, contributing to a 14.14% stock price appreciation since previous coverage.
Management's conservative 2026 guidance sets a baseline that could be exceeded, with projected high-single-digit EPS growth and 3-6% core revenue growth.
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 21, 2026 | $2.11+9.9% vs $1.92 | $6.6B-0.1% vs $6.6B |
Q3 2026 Jul 21, 2026 | $1.94+4.9% vs $1.85 | $6.3B+2.4% vs $6.1B |
Q2 2026 Apr 21, 2026 | $2.06+6.2% vs $1.94 | $6.0B-0.5% vs $6.0B |
Q1 2026 Jan 28, 2026 | $2.23+3.2% vs $2.16 | $6.8B+0.4% vs $6.8B |
Danaher (DHR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Compass Wealth Management LLC reduced its holdings in shares of Danaher Corporation (NYSE: DHR) by 9.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 44,242 shares of the conglomerate's stock after selling 4,464 shares during the period. Danaher comprises approximately 1.9%

Investors interested in Medical Services stocks are likely familiar with Labcorp Holdings (LH) and Danaher (DHR). But which of these two stocks is more attractive to value investors?

Danaher Corporation is rated hold, as the stock trades at a small premium and offers an 8.85% expected return, below my threshold. Q3 earnings showed solid performance: revenue up 8.3% YoY to $6.55B, adjusted EPS of $2.11, and strong segment growth, especially in Diagnostics. Key headwinds include respiratory revenue volatility and pricing pressure from China's volume-based procurement, despite some recent positive trends.
Benchmark DHR against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Danaher Corporation (DHR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $230.25 | $161.86B | 45.68 | 2.9% | 14.71% | 7.08% | 0.54% | |
| $694.76 | $258.19B | 39.16 | 3.91% | 14.96% | 13.3% | — | |
| $174.76 | $49.36B | 38.24 | 6.73% | 19.53% | 20.47% | — | |
| $457.60 | $34.22B | 42.53 | 6.99% | 1.75% | 0.81% | — | |
| $381.57 | $10.27B | 13.69 | 0.65% | 8.59% | 3.15% | — | |
| $61.31 | $9.33B | -408.73 | 2.08% | -2.03% | -2.87% | — |
Danaher Corporation (DHR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Danaher Corporation (DHR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 21, 2026·SEC
Oct 13, 2026·SEC
Aug 3, 2026·SEC
Get notified when DHR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Danaher Corporation (DHR) stock FAQ — growth, dividends, profitability & financials explained
Danaher Corporation (DHR) reported $25.61B in revenue for fiscal year 2025. This represents a 1313% increase from $1.81B in 1996.
Danaher Corporation (DHR) grew revenue by 2.9% over the past year. Growth has been modest.
Yes, Danaher Corporation (DHR) is profitable, generating $4.33B in net income for fiscal year 2025 (14.7% net margin).
Yes, Danaher Corporation (DHR) pays a dividend with a yield of 0.54%. This makes it attractive for income-focused investors.
Danaher Corporation (DHR) has a return on equity (ROE) of 7.1%. This is below average, suggesting room for improvement.
Danaher Corporation (DHR) generated $5.73B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.